CAMKK2 and ovarian carcinoma: Pharmacological inhibition of CaMKKβ/2 with STO-609 impairs the tumorigenicity of liver cancer cells in vivo, possibly mediated by CaMKIV [106], and suppresses CaMKKβ/2-mediated PKB/Akt phosphorylation in ovarian cancer cell lines, resulting in lower cell growth and viability [32].